Showing results (361-370 of 567) with videos related to
Sort By:
Pageof 57
Archives of Environmental Contamination and Toxicology|February 10, 2000
Phototoxic evaluation of marine sediments collected from a PAH-contaminated siteB L Boese, R J Ozretich, J O Lamberson, et al.The Annals of Thoracic Surgery|October 6, 1999
Results of the Collis-Nissen gastroplasty in patients with Barrett's esophagusL Q Chen, D Nastos, C Y Hu, et al.Journal of the American Medical Informatics Association : JAMIA|March 26, 2013
An ontology-driven, diagnostic modeling systemPeter J Haug, Jeffrey P Ferraro, John Holmen, et al.Journal of the American Academy of Dermatology|September 17, 2019
Achieving consensus on patient-reported outcome measures in clinical practice for inflammatory skin disordersLourdes Perez-Chada, Vanina L Taliercio, Alice B Gottlieb, et al.International Journal of Women'S Dermatology|May 12, 2017
Developing classification criteria for discoid lupus erythematosus: an update from the World Congress of Dermatology 2015 meetingScott A Elman, Filippa Nyberg, Fukumi Furukawa, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|January 23, 2026
Litifilimab efficacy on skin outcomes in cutaneous lupus erythematosus in the Phase 2 LILAC studyVictoria P Werth, Joseph F Merola, Richard Furie, et al.Dermatology and Therapy|March 13, 2022
Simultaneous Nail and Skin Clearance in Ixekizumab Head-to-Head Trials for Moderate-to-Severe Psoriasis and Psoriatic ArthritisBoni E Elewski, Andrew Blauvelt, Gaia Gallo, et al.Journal of the American Academy of Dermatology|June 1, 2020
Bimekizumab for patients with moderate to severe plaque psoriasis: 60-week results from BE ABLE 2, a randomized, double-blinded, placebo-controlled, phase 2b extension studyAndrew Blauvelt, Kim A Papp, Joseph F Merola, et al.The Journal of Rheumatology|July 15, 2024
Report of the IDEOM Meeting Adjacent to the GRAPPA 2023 Annual MeetingGretchen D Ball, Danielle Yee, Arianna J Zhang, et al.Rheumatology and Therapy|October 15, 2022
Efficacy and Safety of Upadacitinib in Patients with Psoriatic Arthritis: 2-Year Results from the Phase 3 SELECT-PsA 1 StudyIain B McInnes, Koji Kato, Marina Magrey, et al.Pageof 57